The Experts below are selected from a list of 204 Experts worldwide ranked by ideXlab platform
Giuseppe Giaccone - One of the best experts on this subject based on the ideXlab platform.
-
Teniposide alone and in Combination Chemotherapy in small cell lung cancer.
Seminars in oncology, 1992Co-Authors: Giuseppe GiacconeAbstract:Teniposide is one of the most active agents against small cell lung cancer (SCLC). In a phase II study, teniposide achieved a 90% response rate in 33 untreated elderly patients. At our institution, teniposide produced a 34% response rate in a group of 44 unselected patients. Pilot studies of Combination Chemotherapy with teniposide have recently been initiated. A phase II trial with teniposide, vincristine, methotrexate, and cyclophosphamide in SCLC patients was started, based on demonstration of experimental synergy between these drugs. Chest irradiation was also given to patients with limited disease who responded to Chemotherapy, and prophylactic cranial irradiation was given to complete responders (CRs). A response rate of 78% with 22% CRs was achieved in 32 evaluable previously untreated SCLC patients; median durations of response and survival were 252 and 311 days, respectively. Main side effects were myelosuppression, mucositis, and peripheral neuropathy. This teniposide Combination Chemotherapy compares favorably with other reported active regimens in SCLC. Further trials will determine whether the introduction of teniposide in Combination Chemotherapy is able to improve the outcome of SCLC.
Kenji Murakami - One of the best experts on this subject based on the ideXlab platform.
-
Combination Chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma.
International journal of clinical oncology, 2009Co-Authors: Satoshi Tanida, Hiromi Kataoka, Eiji Kubota, Yoshinori Mori, Makoto Sasaki, Naotaka Ogasawara, Tsuneya Wada, Tsutomu Mizoshita, Takaya Shimura, Kenji MurakamiAbstract:Malignant peritoneal mesothelioma is a rare neoplasm with a rapidly fatal course. The response of this disease to treatment is poor because it tends to be advanced at diagnosis and tends to have inherent resistance to chemotherapeutic treatment. We describe three patients with malignant peritoneal mesothelioma who received Combination Chemotherapy with cisplatin and gemcitabine. After a histopathological diagnosis of epithelial-type malignant peritoneal mesothelioma, all patients underwent systemic Chemotherapy because of the advanced disease stage. Moreover, one patient would have been at high risk of cardiac events, because of congenital heart malformation if complete surgical resection had been performed. This Chemotherapy achieved a partial response in two patients, but had no effect in one. Combination Chemotherapy with cisplatin and gemcitabine may prove to be one of the recommended treatments for patients with malignant peritoneal mesothelioma in the near future.
Satoshi Tanida - One of the best experts on this subject based on the ideXlab platform.
-
Combination Chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma.
International journal of clinical oncology, 2009Co-Authors: Satoshi Tanida, Hiromi Kataoka, Eiji Kubota, Yoshinori Mori, Makoto Sasaki, Naotaka Ogasawara, Tsuneya Wada, Tsutomu Mizoshita, Takaya Shimura, Kenji MurakamiAbstract:Malignant peritoneal mesothelioma is a rare neoplasm with a rapidly fatal course. The response of this disease to treatment is poor because it tends to be advanced at diagnosis and tends to have inherent resistance to chemotherapeutic treatment. We describe three patients with malignant peritoneal mesothelioma who received Combination Chemotherapy with cisplatin and gemcitabine. After a histopathological diagnosis of epithelial-type malignant peritoneal mesothelioma, all patients underwent systemic Chemotherapy because of the advanced disease stage. Moreover, one patient would have been at high risk of cardiac events, because of congenital heart malformation if complete surgical resection had been performed. This Chemotherapy achieved a partial response in two patients, but had no effect in one. Combination Chemotherapy with cisplatin and gemcitabine may prove to be one of the recommended treatments for patients with malignant peritoneal mesothelioma in the near future.
S H Kaufmann - One of the best experts on this subject based on the ideXlab platform.
-
Topotecan in Combination Chemotherapy.
Seminars in oncology, 1997Co-Authors: E K Rowinsky, S H KaufmannAbstract:The safety and efficacy of Combination Chemotherapy regimens containing topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I-targeting drug that has demonstrated significant antitumor activity in a wide range of human tumors, and various classes of antineoplastic agents is currently being evaluated. To date, phase I and pharmacologic studies of topotecan combined with cisplatin, carboplatin, doxorubicin, and etoposide have been performed in adult and pediatric patients with solid tumors. Combination regimens consisting of topotecan combined with cytarabine, cyclophosphamide, and carboplatin also have been studied in patients with refractory leukemia. Myelosuppression, primarily neutropenia, has been the principal dose-limiting toxicity of these Combination regimens. Major responses have been observed in many early studies. Both the toxicologic and antineoplastic effects have exhibited sequence dependence in preclinical and phase I studies, especially in evaluations of topotecan combined with alkylating agents and topoisomerase II-targeting drugs. At this juncture, additional phase I and II trials are required to evaluate the toxicity and efficacy of topotecan in Combination with other agents and address critical issues related to optimal drug dosing and sequencing.
Naotaka Ogasawara - One of the best experts on this subject based on the ideXlab platform.
-
Combination Chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma.
International journal of clinical oncology, 2009Co-Authors: Satoshi Tanida, Hiromi Kataoka, Eiji Kubota, Yoshinori Mori, Makoto Sasaki, Naotaka Ogasawara, Tsuneya Wada, Tsutomu Mizoshita, Takaya Shimura, Kenji MurakamiAbstract:Malignant peritoneal mesothelioma is a rare neoplasm with a rapidly fatal course. The response of this disease to treatment is poor because it tends to be advanced at diagnosis and tends to have inherent resistance to chemotherapeutic treatment. We describe three patients with malignant peritoneal mesothelioma who received Combination Chemotherapy with cisplatin and gemcitabine. After a histopathological diagnosis of epithelial-type malignant peritoneal mesothelioma, all patients underwent systemic Chemotherapy because of the advanced disease stage. Moreover, one patient would have been at high risk of cardiac events, because of congenital heart malformation if complete surgical resection had been performed. This Chemotherapy achieved a partial response in two patients, but had no effect in one. Combination Chemotherapy with cisplatin and gemcitabine may prove to be one of the recommended treatments for patients with malignant peritoneal mesothelioma in the near future.